


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): A compound Compounds of the formula I



in which

R¹, R² are each, independently of one another, H, =O, Hal, A, ethynyl, OR³, N(R³)₂, NO₂, CN, N₃, COOR³, CON(R³)₂, -(C(R⁴)₂)_n-Ar, -(C(R⁴)₂)_n-Het, -(C(R⁴)₂)_n-cycloalkyl, -OCOR³, -OCON(R³)₂, NR³COA, or NR³SO₂A,

R¹ and R² together are alternatively a bicyclically or spirocyclically bonded 3- to 7-membered carbocyclic or heterocyclic ring having from 0 to 3 N, O and/or S atoms,

R³ is H, A, H-C≡C-CH₂-, CH₃-C≡C-CH₂-, -CH₂-CH(OH)-CH₂OH, -CH₂-CH(OH)-CH₂NH₂, -CH₂-CH(OH)-CH₂Het', -(C(R⁴)₂)_n-Ar', -(C(R⁴)₂)_n-Het', -(C(R⁴)₂)_n-cycloalkyl, -(C(R⁴)₂)_n-COOA or -(C(R⁴)₂)_nN(R⁴)₂,

R⁴ is H or A,

W is N, CR³ or an sp²-hybridised carbon atom,

E together with W is a 3- to 7-membered saturated carbocyclic or heterocyclic ring having from 0 to 3 N, from 0 to 2 O and/or from 0 to 2 S atom which optionally contains may contain a double bond,

D is a monocyclic or bicyclic, aromatic carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms which is unsubstituted or monosubstituted or polysubstituted by Hal, A, OR³, N(R³)₂, NO₂, CN, COOR³ or CON(R³)₂,

G is -(C(R⁴)₂)_n-, -(C(R⁴)₂)_nNR³-, -(C(R⁴)₂)_nO-, -(C(R⁴)₂)_nS- or -(C(R⁴)=C(R⁴))_n-,

X is -(C(R⁴)₂)_nCONR³[C(R⁴)₂]_n-, -(C(R⁴)₂)_nNR³CO[C(R⁴)₂]_n-, -(C(R⁴)₂)_nNR³[C(R⁴)₂]_n-, -(C(R⁴)₂)_nO[C(R⁴)₂]_n-,

$-[C(R^4)_2]_nCO[C(R^4)_2]_n-$ or $-[C(R^4)_2]_nCOO[C(R^4)_2]_n-$,

Y is alkylene, cycloalkylene, Het-diyl or Ar-diyl,

T is a monocyclic or bicyclic, saturated or unsaturated carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms which is monosubstituted or disubstituted by =O, =S, =NR³, =N-CN, =N-NO₂, =NOR³, =NCOR³, =NCOOR³ or =NOCOR³ and which is optionally further may furthermore be monosubstituted, disubstituted or trisubstituted by R³, Hal, A, -[C(R⁴)₂]_n-Ar, -[C(R⁴)₂]_n-Het, -[C(R⁴)₂]_n-cycloalkyl, OR³, N(R³)₂, NO₂, CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³, SO₂NR³ and/or S(O)_nA,

A is unbranched or branched alkyl having 1-10 carbon atoms in which one or two CH₂ groups are each optionally may be replaced by O or S atoms and/or by -CH=CH- groups and/or in addition 1-7 H atoms are each optionally may be replaced by F,

Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, OR³, N(R³)₂, NO₂, CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³, SO₂N(R³)₂, S(O)_nA, -[C(R⁴)₂]_n-COOR³ or -O[C(R⁴)₂]_o-COOR³,

Ar' is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, OR⁴, N(R⁴)₂, NO₂, CN, COOR⁴, CON(R⁴)₂, NR⁴COA, NR⁴CON(R⁴)₂, NR⁴SO₂A, COR⁴, SO₂N(R⁴)₂, S(O)_nA, -[C(R⁴)₂]_n-COOR⁴ or -O[C(R⁴)₂]_o-COOR⁴,

Het is a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having from 1 to 4 N, O and/or S atoms which is may be unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, -[C(R⁴)₂]_n-Ar, -[C(R⁴)₂]_n-Het', -[C(R⁴)₂]_n-cycloalkyl, OR³, N(R³)₂, NR³CON(R³)₂, NO₂, CN, -[C(R⁴)₂]_n-COOR³, -[C(R⁴)₂]_n-CON(R³)₂, NR³COA, NR³SO₂A, COR³, SO₂NR³, S(O)_mA and/or carbonyl oxygen,

Het' is a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having from 1 to 4 N, O and/or S atoms which is may be unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, =S, =N(R⁴)₂, Hal, A,

OR^4 , $\text{N}(\text{R}^4)_2$, NO_2 , CN , COOR^4 , $\text{CON}(\text{R}^4)_2$, NR^4COA , $\text{NR}^4\text{CON}(\text{R}^4)_2$,
 $\text{NR}^4\text{SO}_2\text{A}$, COR^4 , SO_2NR^4 and/or $\text{S}(\text{O})_n\text{A}$,

Hal is F, Cl, Br or I,

n is 0, 1 or 2, and

o is 1, 2 or 3; [[,]]

or a and pharmaceutically usable derivative, solvate, salt, or stereoisomer derivatives,
solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

2. (Currently Amended): A compound Compounds according to Claim 1, ~~in which~~
~~wherein~~ D is a monocyclic or bicyclic, aromatic carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms which is unsubstituted or monosubstituted or disubstituted by Hal, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof,~~
~~including mixtures thereof in all ratios.~~

3. (Currently Amended): A compound Compounds according to Claim 1, ~~in which~~
~~wherein~~ D is phenyl, pyridyl, thienyl, furyl or imidazolyl, ~~each of which in each case~~ is monosubstituted or disubstituted by Hal, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

4. (Currently Amended): A compound Compounds according to claim 1, ~~in which~~
~~wherein~~ R^1 [[,]] ~~and~~ R^2 are each, independently of one another, H, =O, COOR^3 , OH, OA, NH_2 , alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N_3 , ethynyl, vinyl, allyloxy, NHCOA , NHSO_2A , OCH_2COOA or OCH_2COOH , ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

5. (Currently Amended): A compound Compounds according to claim 1, ~~in which~~
~~wherein~~ G is $(\text{CH}_2)_n$, $(\text{CH}_2)_n\text{NH}-$, $-\text{CH}=\text{CH}-$ or $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

6. (Currently Amended): A compound Compounds according to claim 1, ~~in which wherein X is -[C(R⁴)₂]_nCONR³[C(R⁴)₂]_n-, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

7. (Currently Amended): A compound Compounds according to claim 1, ~~in which wherein X is -CONH- or -CON(CH₂COOA)-, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

8. (Currently Amended): A compound Compounds according to claim 1, ~~in which wherein Y is cycloalkylene, Het-diyl or Ar-diyl, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

9. (Currently Amended): A compound Compounds according to claim 1, ~~in which wherein Y is pyridinediyl, piperidinediyl, cyclohexylene, or phenylene which is unsubstituted or monosubstituted or disubstituted by A, OA, Cl, F, COOCH₃, COOH, phenoxy or aminocarbonyl, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

10. (Currently Amended): A compound Compounds according to claim 1, ~~in which wherein T is a monocyclic, saturated or unsaturated heterocyclic ring having 1 to 2 N and/or O atoms which is monosubstituted or disubstituted by =O, =S or =NH₂, and which is optionally further may be monosubstituted or disubstituted by Hal, A and/or OA, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

11. (Currently Amended): A compound Compounds according to claim 1, ~~in which wherein T is piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, imidazolidinyl, thiazolyl or 1,4-oxazepanyl, each of which is monosubstituted or disubstituted by =O or =NH₂ and where the radicals which is optionally further may also be monosubstituted or disubstituted by Hal, A and/or OA, and pharmaceutically usable~~

~~derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

12. (Currently Amended): A compound Compounds according to claim 1, ~~in which wherein~~ Ar is phenyl which is unsubstituted or monosubstituted or disubstituted by Hal, A, OA, SO₂A, COOR², SO₂NH₂, CN, COOA, COOH or phenoxy, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

13. (Currently Amended): A compound Compounds according to claim 1, ~~in which wherein~~

D is a monocyclic or bicyclic, aromatic carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms, ~~which is unsubstituted or monosubstituted or disubstituted by Hal,~~

R¹ and [[,]] R² are each, independently of one another, H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, NHCOA, NHSO₂A, OCH₂COOA or OCH₂COOH, ~~or~~ R¹ and R² together are alternatively a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R³ is H, A, phenyl, benzyl or [C(R⁴)₂]_nCOOA,

R⁴ is H or A,

W is N, CR³ or an sp²-hybridised carbon atom,

E together with W is a 3- to 7-membered saturated carbocyclic or heterocyclic ring having from 0 to 3 N, from 0 to 2 O and/or from 0 to 2 S atoms, and which optionally contains ~~may contain~~ a double bond,

G is (CH₂)_n, (CH₂)_nNH-, -CH=CH- or -CH=CH-CH=CH-,

X is -[C(R⁴)₂]_nCONR³[C(R⁴)₂]_n-,

Y is cycloalkylene, Het-diyl or Ar-diyl,

Ar is phenyl which is unsubstituted or monosubstituted or disubstituted by Hal, A, OA, SO₂A, COOR², SO₂NH₂, CN, COOA, COOH or phenoxy,

T is a monocyclic, saturated or unsaturated heterocyclic ring having 1 to 2 N and/or O atoms which is monosubstituted or disubstituted by =O, =S or =NH, and which is optionally further ~~may be~~ monosubstituted or disubstituted by Hal, A and/or OA,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally may be replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2;

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

14. (Currently Amended): A compound Compounds according to claim 1, in which wherein

D is phenyl, pyridyl, thienyl, furyl or imidazolyl, each of which in each case is monosubstituted or disubstituted by Hal,

R¹ and [[,]] R² are each, independently of one another, H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, NHCOA, NSO₂A, OCH₂COOA or OCH₂COOH, or R¹ and R² together are alternatively a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R³ is H, A or CH₂COOA,

R⁴ is H or A,

W is N, CR³ or an sp²-hybridised carbon atom,

E together with W is a 3- to 7-membered saturated carbocyclic or heterocyclic ring having from 0 to 3 N, from 0 to 2 O and/or from 0 to 2 S atoms, and which optionally contains may contain a double bond,

G is (CH₂)_n, (CH₂)_nNH-, -CH=CH- or -CH=CH-CH=CH-,

X is -CONH- or -CON(CH₂COOA)-,

Y is pyridinediyl, piperidinediyl, cyclohexylene, or phenylene which is unsubstituted or monosubstituted or disubstituted by A, OA, Cl, F, COOCH₃, COOH, phenoxy or aminocarbonyl,

T is piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, imidazolidinyl, thiazolyl or 1,4-oxazepanyl, each of which in each case is monosubstituted or disubstituted by =O or =NH₂ and which is optionally further where the radicals may also be monosubstituted or disubstituted by Hal, A and/or OA,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally may be replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2;

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

15. (Currently Amended): A compound Compounds according to claim 1, in which wherein

D is phenyl, pyridyl or thienyl, each of which in each case is monosubstituted or disubstituted by Hal,


R¹ is H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, -OCOR³, NHCOA or NSO₂A,

R² is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R¹ and R² together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R³ is H or A,

R⁴ is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl,

thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is (CH₂)_n or (CH₂)_nNH-,

X is CONH,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo-[2.2.2]octan-2-yl, each of which in each case is monosubstituted or disubstituted by carbonyl oxygen,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H

atoms are each optionally may be replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2;

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

16. (Currently Amended): A compound Compounds according to claim 1, ~~in which wherein~~

D is phenyl, pyridyl or thienyl, each of which in each case is monosubstituted or disubstituted by Hal,


R¹ is H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, -OCOR³, NHCOA or NHSO₂A,

R² is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R¹ and R² together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R³ is H or A,

R⁴ is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl,

thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is (CH₂)_n or (CH₂)_nNH-,

X is CONH,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally may be replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2;

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

17. (Currently Amended): A compound Compounds according to claim 1, ~~in which wherein X is -[C(R⁴)₂]_nCONR³[C(R⁴)₂]_n- or -[C(R⁴)₂]_nCO[C(R⁴)₂]_n-, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

18. (Currently Amended): A compound Compounds according to claim 1, ~~in which wherein X is CONH or COCH₂, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

19. (Currently Amended): A compound Compounds according to claim 1, ~~in which wherein~~

D is phenyl, pyridyl or thienyl, each of which is monosubstituted or disubstituted by Hal,


R¹ is H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, -OCOR³, NHCOA or NHSO₂A,

R² is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R¹ and R² together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R³ is H or A,

R⁴ is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl,

thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is (CH₂)_n or (CH₂)_nNH-,

X is CONH or COCH₂,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally may be replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2,

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

20. (Currently Amended): A compound Compounds according to claim 1, ~~in~~ which wherein

D is phenyl, pyridyl or thienyl, each of which is monosubstituted or disubstituted by Hal,


R¹ is H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, -OCOR³, NHCOA, NHSO₂A, H-C≡C-CH₂-, CH₃-C≡C-CH₂-O-, -O-CH₂-CH(OH)-CH₂OH, -O-CH₂-CH(OH)-CH₂NH₂ or -O-CH₂-CH(OH)-CH₂Het',

R² is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R¹ and R² together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R³ is H or A,

R⁴ is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl,

thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is (CH₂)_n or (CH₂)_nNH-,

X is CONH or COCH₂,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen,

Het' is a saturated 3-6-membered heterocyclic ring having from 1 to 3 N and/or O atoms, which is may be unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, Hal, A, OH, NH₂, NO₂, CN, COOA or CONH₂,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally may be replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

21. (Currently Amended): A compound Compounds according to claim 1, in which wherein

D is phenyl, pyridyl or thienyl, each of which is monosubstituted or disubstituted by Hal,


R¹ is ethynyl, vinyl, allyloxy, CH₃-C≡C-CH₂-O-, -O-CH₂-CH(OH)-CH₂OH, -O-CH₂-CH(OH)-CH₂NH₂ or -O-CH₂-CH(OH)-CH₂Het',

R² is H or OH,

R¹ and R² together can also be are alternatively a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R³ is H or A,

R⁴ is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl,

thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is (CH₂)_n or (CH₂)_nNH-,

X is CONH, CO, COO or COCH₂,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo-

[2.2.2]octan-2-yl, each of which in each case is monosubstituted or disubstituted by carbonyl oxygen or OA,

Het' is a saturated 3-6-membered heterocyclic ring having from 1 to 3 N and/or O atoms, which is ~~may~~ be unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, Hal, A, OH, NH₂, NO₂, CN, COOA or CONH₂,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally may be replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2;

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

22. (Currently Amended): A compound Compounds according to claim 1, in which wherein

D is phenyl, pyridyl, thienyl, furyl or imidazolyl, each of which is monosubstituted or disubstituted by Hal,


R¹ is H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, NHCOA, NHSO₂A, OCH₂COOA or OCH₂COOH,

R² is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R¹ and R² together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R³ is H or A,

R⁴ is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is (CH₂)_n, (CH₂)_nNH-, -CH=CH- or -CH=CH-CH=CH-,

X is CONH, COCH₂ or -CON(CH₂COOA)-,

Y is pyridinediyl, piperidinediyl, cyclohexylene, or phenylene, which is unsubstituted or monosubstituted or disubstituted by A, OA, Cl, F, COOCH₃, COOH, phenoxy or aminocarbonyl,

T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally may be replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2;

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.~~

23. (Currently Amended): A compound Compounds according to Claim 1, wherein said compound is selected from: the group consisting of

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[3-trifluoromethyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-piperidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxo-2H-pyrazin-1-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-2,5-

dihydropyrrole-1,2-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide,

N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5R)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2H-pyrazin-1-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2H-pyrazin-1-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[3-chloro-4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(S)-thiazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(S)-1,1-dioxo-1 λ ⁶-thiazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-thiazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-1,1-dioxo-1 λ ⁶-thiazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(R)-thiazolidine-3,4-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxamide,

N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxamide,

N-[4-(2-oxo-2H-pyridin-1-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{{[4-(2-oxo-2H-pyrazin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{{[3-fluoro-4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(R)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(R)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxopyrazin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[3-fluoro-4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,3R)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,3S)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-3,4-dihydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-azidopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-aminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-azidopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-aminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-acetaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-acetaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-propoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,

(3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl]pyrrolidin-3-yl isobutyrate,

(3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl]pyrrolidin-3-yl propionate,

(3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl]pyrrolidin-3-yl acetate,

4-N-[(4-chlorophenyl)]-5-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-1,3-dioxolane-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{{4-(2-oxo-1*H*-pyridin-1-yl)phenyl]}-1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,

1-N-[4-chlorophenyl)]-2-N-{{4-(3-oxomorpholin-4-yl)phenyl]}-1-BOC-piperazine-1,2-dicarboxamide,

1-N-[4-chlorophenyl)]-2-N-{{4-(3-oxomorpholin-4-yl)phenyl]} piperazine-1,2-dicarboxamide,

1-N-[4-chlorophenyl)]-2-N-{{4-(3-oxomorpholin-4-yl)phenyl]}-1,3-oxazinane-3,4-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-(3-oxomorpholin-4-yl)phenyl]}-(2*R*,4*S*)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide,

6-N-[(4-chlorophenyl)]-7-N-{{4-(3-oxomorpholin-4-yl)phenyl]}-4-oxa-6-azaspiro[2.4]heptane-6,7-dicarboxamide,

1-N-[(6-chloropyridin-3-yl)]-2-N-{{4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(6-chloropyridin-3-yl)]-2-N-{{4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2*R*,4*S*)-4-acetaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-(3-oxomorpholin-4-yl)phenyl]}-(2*R*,4*S*)-4-butylsulfonylaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-(3-oxomorpholin-4-yl)phenyl]}-(*R*)-4-oxopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2*R*,4*S*)-4-aminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(*S*)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-*(2R,4R)-1-[2-(4-chlorophenyl)acetyl]*-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(4-chlorobenzoyl)-4-hydroxypyrrolidine-2-carboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]} }-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxo-2H-pyridin-1-yl)phenyl]} }-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]} }-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxo-2H-pyrazin-1-yl)phenyl]} }-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]} }-(2R,4S)-4-(2-methylpropanoylamino)pyrrolidine-1,2-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(1-1*H*-indol-3-ylmethanoyl)-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(1-1*H*-indol-6-ylmethanoyl)-4-hydroxypyrrolidine-2-carboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]} }-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]} }-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]} }-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]} }-(2R,4S)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]} }-(2R,4S)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]} }-4,4-difluoro-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[2-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]} }-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

2-N-[(4-chlorophenyl)]-1-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

2-N-[(4-chlorophenyl)]-1-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(S)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxo-3-methoxy-2H-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxo-3-methoxy-2H-pyridin-1-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

N-(4-chlorophenyl)-(R)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(S)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}-4-methoxypyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(2R,4S)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}-4-methoxypyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(2S,4R)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}-4-methoxypyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(S)-1-{2-[4-(2-oxo-1H-pyridin-1-yl)phenyl]acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(S)-1-{2-[4-(2-oxopyrrolidin-1-yl)phenyl]acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(R)-1-{2-[4-(2-oxopyrrolidin-1-yl)phenyl]acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(R)-1-[4-(2-oxopiperidin-1-yl)benzoyl]pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(R)-1-[4-(2-oxopiperidin-1-yl)phenyloxycarbonyl]pyrrolidine-2-carboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(2*R*,4*R*)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2*R*,4*R*)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2*R*,4*R*)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2*R*,4*R*)-4-(but-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2*R*,4*R*)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2*R*,4*R*)-4-(2-hydroxy-3-pyrrolidin-1-ylpropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2*R*,4*R*)-4-(3-amino-2-hydroxypropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxo-1*H*-pyrazin-1-yl)phenyl]}-(*R*)-2,5-dihdropyrrole-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]}-(*R*)-2,5-dihdropyrrole-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(*R*)-2,5-dihdropyrrole-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(*R*)-2,5-dihdropyrrole-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2*S*,3*S*)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2*S*,4*S*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[2-methoxycarbonyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[2-carboxy-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,3S,4R)-3,4-dihydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-allyloxyppyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(prop-2-nyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-(prop-2-nyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(methoxycarbonylmethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(carboxymethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-bromophenyl)]-2-N-{{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{N-methoxycarbonylmethyl-N'-[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)cyclohexan-1-yl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-iminopyrrolidin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, ESI 442;

1-N-[(4-chlorophenyl)]-2-N-{{[3-methyl-4-(2-iminopyrrolidin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, ESI 456;

1-N-[(4-chlorophenyl)]-2-N-{{[2-[(E)-cyanimino]imidazolidin-1-yl]phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, ESI 468;

1-N-[(4-chlorophenyl)]-2-N-{{4-(2-imino-5-methylthiazol-3-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, ESI 473;

1-N-[(4-chlorophenyl)]-2-N-{{[2-aminocarbonyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, ESI 502;

1-N-[(4-chlorophenyl)]-2-N-{{4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxy-2-methylpyrrolidine-1,2-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-thiophen-3-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(2E,4E)-5-phenylpenta-2,4-dienyloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-methylfuran-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-thiophen-2-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-4-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-4-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-bromothiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-bromothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-bromothiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-bromothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(R)-1-[4-(2-oxopiperidin-1-yl)benzoyl]pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(S)-1-[4-(2-oxopiperidin-1-yl)benzoyl]pyrrolidine-2-carboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(5-oxo-1,4-oxazepan-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(5-oxo-1,4-oxazepan-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-((S)-2-methyl-3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-((S)-2-methyl-3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-((R)-2-methyl-3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-((R)-2-methyl-3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)-2-phenoxyphenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-((R)-2-methyl-3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-3-N-{[4-(3-oxomorpholin-4-yl)phenyl]}piperidine-1,3-dicarboxamide,

1-N-[(4-chlorophenyl)]-3-N-{{3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}piperidine-1,3-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2-methoxyethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxo-1,4-oxazepan-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[2-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[2-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

24. (Currently Amended): A pyrrolidinecarboxylic Pyrrolidinecarboxylic acid compound derivatives selected from: the group consisting of

1-N-[(4-chlorophenyl)]-2-N-[(1'-methyl-[1,4']bipiperidinyl-4-yl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[(3,4,5,6-tetrahydro-2H-1,4'-bipyridinyl-4-yl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[(3,4,5,6-tetrahydro-2H-1,4'-bipyridinyl-4-yl)]-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-(4-pyridin-4-yl)piperazine-1-carbonyl)pyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-[4-(2-methoxyphenyl)piperazine-1-carbonyl]pyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-2-[4-(4-fluorophenyl)piperazine-1-carbonyl]-4-hydroxypyrrolidine-1-carboxamide,


N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-[4-hydroxy-4-(4-methoxyphenyl)piperidine-1-carbonyl]pyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-(4-pyridin-2-yl)pyrrolidine-1-carboxamide,
N-(4-chlorophenyl)-(2R,4R)-2-[4-(4-ethylpiperazin-1-yl)piperidine-1-carbonyl]-4-hydroxypyrrolidine-1-carboxamide,
N-(4-chlorophenyl)-(2R,4R)-2-[4-(4,6-dimethylpyrimidin-2-yl)piperazine-1-carbonyl]-4-hydroxypyrrolidine-1-carboxamide,
N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-[4-(1-methylpiperidin-4-yl)piperazine-1-carbonyl]pyrrolidine-1-carboxamide,
1-N-[(4-chlorophenyl)]-2-N-{{[2-(2-dimethylaminoethoxy)-4-morpholin-4-ylphenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
1-N-[(4-chlorophenyl)]-2-N-[(2-ethoxy-4-morpholin-4-ylphenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
1-N-[(4-chlorophenyl)]-2-N-[(4-morpholin-4-yl-2-propoxyphenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

25. (Currently Amended): A cyclopentanecarboxylic Cyclopentanecarboxylic acid derivatives compound selected from: the group consisting of
N-[4-(3-oxomorpholin-4-yl)phenyl]-(rac)-2-[3-(4-chlorophenyl)-ureido]cyclopentanecarboxamide,
N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-(rac)-2-[3-(4-chlorophenyl)-ureido]cyclopentanecarboxamide,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

26. (Currently Amended): A process Process for the preparation of compounds of the formula I according to claim 1 and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, characterised in that said process comprising
a) for the preparation of compounds of the formula I in which W is N and G is NH,

a compound of the formula II



in which

R^1 , R^2 , E, X, Y and T are as defined in Claim 1, and W is N,

is reacted with a compound of the formula III



in which

D is as defined in Claim 1,

or


b) for the preparation of compounds of the formula I in which X is -
[C(R⁴)₂]_nCONR³[C(R⁴)₂]_n-,

a compound of the formula IV



in which R^3 , n , Y and T are as defined in Claim 1,

is reacted with a compound of the formula V




in which

L is Cl, Br, I or a free or reactively functionally modified OH group, and R¹, R², R⁴, D, E, G, W and n are as defined in Claim 1,

or

c) for the preparation of compounds of the formula I in which W is N,

a compound of the formula II



in which

R^1 , R^2 , E, X, Y and T are as defined in Claim 1, and W is N,

is reacted with a compound of the formula VI



in which

D and G are as defined in Claim 1, and L is Cl, Br, I or a free or reactively functionally modified OH group,

and/or

a base or acid of the formula I is converted into one of its salts.

27. Cancelled

28. Cancelled.

29. (Currently Amended): A medicament composition Medicament comprising at least one compound of the formula I according to claim 1 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and, if desired, one or more excipients and/or adjuvants.

30. (Currently Amended): A medicament composition Medicament comprising at least one compound of the formula I according to claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.


31. (Currently Amended): A method Use of compounds according to claim 1 and/or physiologically acceptable salts, salts and solvates thereof for the preparation of a medicament for the treatment of a patient suffering from thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, comprising administering to said patient an effective amount of a compound according to claim 1.

32. (Currently Amended): A kit comprising Set (kit) consisting of separate packs of:

- (a) an effective amount of a compound of the formula I according to claim 1 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios,
and
- (b) an effective amount of a further medicament active ingredient.

33. (Currently Amended): A method according to claim 31, further comprising administering to said patient Use of compounds of the formula I according to claim 1 one or more of Claims 1 to 23 or of compounds of Claims 24 and 25 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases,
in combination with at least one further medicament active ingredient.

34. (Currently Amended): An intermediate compound Intermediate compounds of the formula I-1:




in which

D is phenyl, pyridyl, thienyl, furyl or imidazolyl, each of which in each case is monosubstituted or disubstituted by Hal,

R¹ is H, OH, OA, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or ethynyl,

R² is H, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4-

or 3,5-diyl,

G is (CH₂)_n, (CH₂)_nNH-, -CH=CH- or -CH=CH-CH=CH-,

X is COOH,

A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

Hal is F, Cl, Br or I, and


n is 0, 1 or 2,

or an isomer or salt and isomers and salts thereof.

35. (Currently Amended): A compound according to Claim 34,
wherein said compound is selected from: the group consisting of
3-(4-chlorophenylcarbamoyl)oxazolidine-4-carboxylic acid,
3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxylic acid,
and isomers and salts thereof.

36. (Currently Amended): An intermediate compound selected from: the group consisting of tert-butoxycarbonyl
(2R,4S)- tert-butoxycarbonyl-4-ethynyl-4-hydroxy-pyrrolidine-2-carboxylic acid,
(2R,4S)- BOC 4 ethynyl 4 hydroxy pyrrolidine 2 carboxylic acid,
(2R,4R)- tert-butoxycarbonyl-4-ethynyl-4-hydroxy-pyrrolidine-2-carboxylic acid,
(2R,4R) BOC 4 ethynyl 4 hydroxy pyrrolidine 2 carboxylic acid,
alkyl (2R,4S)- tert-butoxycarbonyl-4-ethynyl-4-hydroxypyrrolidine-2-carboxylate
wherein alkyl has 1, 2, 3, 4, 5 or 6 carbon atoms,
alkyl (2R,4S)- BOC 4 ethynyl 4 hydroxypyrrolidine 2 carboxylate,
alkyl (2R,4R)- tert-butoxycarbonyl-4-ethynyl-4-hydroxypyrrolidine-2-carboxylate
wherein alkyl has 1, 2, 3, 4, 5 or 6 carbon atoms,
alkyl (2R,4R) BOC 4 ethynyl 4 hydroxypyrrolidine 2 carboxylate, where alkyl has 1,
2, 3, 4, 5 or 6 carbon atoms,
and isomers and salts thereof.

37. (Currently Amended): An intermediate compound of the formula I-2



wherein in which


R^1 is H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

N_3 , ethynyl, vinyl, allyloxy, NHCOA , NHSO_2A , OCH_2COOA or OCH_2COOH ,

R^2 is H, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R^1 and R^2 together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R^3 is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl,

X is CONH ,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is piperidin-1-yl, pyrrolidin-1-yl, 1H -pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2H -pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo[2.2.2]octan-2-yl, each of which in each case is monosubstituted or disubstituted by carbonyl oxygen,


A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2,

or an isomer or salt and isomers and salts thereof.

38. (Currently Amended): A compound Compounds according to Claim 37 of the formula I-2a




wherein in which

R^1 is H, =O, COOR^3 , OH, OA, NH_2 , alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N_3 , ethynyl, vinyl, allyloxy, NHCOA , NHSO_2A , OCH_2COOA or OCH_2COOH ,

R^2 is H, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R^3 is H or A,



is pyrrolidine-1,2-diyI,

X is CONH,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo-[2.2.2]octan-2-yl, each of which in each case is monosubstituted or disubstituted by carbonyl oxygen,

A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2,

or an isomer or salt and isomers and salts thereof.

39. (Currently Amended): A compound Compounds according to Claim 38, wherein said compound is selected from: ~~the group consisting of~~

N-[4-(3-oxomorpholin-4-yl)phenyl]-*(S)*-pyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-*(R)*-pyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-*(2R,4R)*-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-*(R)*-4,4-dimethoxypyrrolidine-2-carboxamide,


N-[4-(3-oxomorpholin-4-yl)phenyl]-*(2R,4R)*-4-methoxypyrrolidine-2-carboxamide,

and isomers and salts thereof.

40. (Currently Amended): A medicament composition Medicament according to Claim 30, wherein said at least one compound is comprising 1-*N*-[(4-chlorophenyl)]-2-*N*-{[4-(3-oxomorpholin-4-yl)phenyl]}-*(2R,4R)*-4-hydroxypyrrolidine-1,2-dicarboxamide and/or a pharmaceutically usable derivative, solvate, salt or stereoisomers derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient is aspirin.

41. (Currently Amended): A method Use according to Claim 33, wherein comprising 1-N-[(4-chlorophenyl)-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide and/or pharmaceutically usable derivative, solvate, salt or stereoisomers derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and in combination with aspirin are administered to said patient.

42. (New): A compound according to claim 1, wherein



is pyrrolidine-1,2-diyl,

G is -NH-,

X is CONH,

Y is Ar-diyl,

Ar is phenyl which is substituted or unsubstituted; and

T is pyrrolidin-1-yl, is monosubstituted or disubstituted by carbonyl oxygen.